Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial

Infection and Immunity

Volumn 66, Issue 7, 1998, Pages 3223-3231

  Wedege, E ^a   Hoiby E A ^a   Rosenqvist, E ^a   Bjune, G ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; MEMBRANE ANTIGEN; MENINGOCOCCUS VACCINE;

ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CONVALESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; SERODIAGNOSIS; TREATMENT FAILURE;

EID: 0031816226     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.7.3223-3231.1998     Document Type: Article

References (69)

1. Andersen, S. R., G. Bjune, E. A. Høiby, T. E. Michaelsen, A. Aase, U. Rye, and E. Jantzen. 1997. Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response. Vaccine 15: 1225-1234.
2. Andersen, S. R. Personal communication.
3. Andersen, S. R., G. Bjune, J. Lyngby, K. Bryn, and E. Jantzen. 1995. Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines. Microb. Pathog. 19:159-168.
4. Andersen, S. R., J. Kolberg, E. A. Høiby, E. Namork, D. A. Caugant, L. O. Frøholm, E. Jantzen, and G. Bjune. 1997. Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development. Microb. Pathog. 23:139-155.
5. Barrera O., and J. Swanson. 1987. Antigens that are similar in apparent molecular weight to gonococcal outer membrane protein III. J. Clin. Microbiol. 25:1155-1158.
6. Bjune, G., E. A. Høiby, P. Djupesland, E. Rosenqvist, E. Wedege, P. Aavitsland, and L. O. Frøholm. 1994. Outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway, p. 750-751. In J. Einhorn, C. E. Nord, and S. R. Norrby (ed.), Recent advances in chemotherapy. Proceedings of the 18th International Congress of Chemotherapy, Stockholm, Sweden. American Society for Microbiology, Washington, D.C.
7. Bjune, G., E. A. Høiby, J. K. Grønnesby, Ø. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nøkleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Frøholm, A. Lystad, L. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
8. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, J. Mays, and the Chilean National Committee for Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 9:821-829.
9. Bøvre, K., L. O. Frøholm, P. Gaustad, E. Holten, and E. A. Høiby. 1983. Some agent characteristics and their coexistence related to the occurrence and severity of systemic meningococcal disease in Norway, winter 1981-1982. NIPH Ann. 6:75-84.
10. Brooks, J. L., E. Rosenqvist, G. Bjune, P. R. Lambden, and J. E. Heckels. 1995. Comparison of the class-1 outer membrane protein from B:15:P1.16 Neisseria meningitidis strains isolated from patients previously immunized with a serogroup B outer membrane protein vaccine in Norway. Microb. Pathog. 17:425-430.
11. Bundell, K. R., A. F. Fox, M. Guiver, D. M. Jones, and J. T. Poolman. 1987. The development of an inhibition enzyme-linked immunosorbent assay to detect total antibody to the P1.16 subtype antigen of Neisseria meningitidis in human sera. Serodiagn. Immunother. Infect. Dis. 1:353-361.
12. Carlson, J. D., and M. L. Yarmush. 1992. Antibody assisted protein refolding. Biotechnology 10:86-91.
13. Caugant, D. A., L. O. Frøholm, K. Bøvre, E. Holten, C. E. Frasch, L. F. Mocca, W. D. Zollinger, and R. K. Selander. 1986. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl. Acad. Sci. USA 83:4927-4931.
14. Caugant, D. A., E. A. Høiby, L. O. Frøholm, and P. Brandtzæg. 1996. Polymerase chain reaction for case ascertainment of meningococcal meningitis: application to the cerebrospinal fluids collected in the course of the Norwegian meningococcal serogroup B protection trial. Scand. J. Infect. Dis. 28:149-153.
15. Caugant, D. A., E. A. Høiby, P. Magnus, O. Scheel, T. Hoel, G. Bjune, E. Wedege, J. Eng, and L. O. Frøholm. 1994. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J. Clin. Microbiol. 32: 323-330.
16. Chavez, L. G., and D. G. Benjamin. 1978. Antibody as an immunological probe for studying the refolding of bovine serum albumin. J. Biol. Chem. 253:8081-8086.
17. Claassen, I., J. Meylis, P. van der Ley, C. Peeters, H. Brons, J. Robert, D. Borsboom, A. van der Ark, I. van Straaten, P. Roholl, B. Kuipers, and J. Poolman. 1996. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14:1001-1008.
18. Danelli, M. G. M., C. M. A. Alves, R. C. Bastos, N. M. Batoreu, D. E. Barroso, J. M. Peralta, and C. E. Frasch. 1996. Human immune response to epitopes on the meningococcal outer membrane class 5 protein following natural infection. FEMS Immunol. Med. Microbiol. 15:159-168.
19. Delvig, A. A., E. Wedege, T. E. Michaelsen, E. A. Høiby, P. Brandtzæg, and E. Rosenqvist. 1996. Immune responses to linear epitopes on the PorB protein of Neisseria meningitidis in patients with systemic meningococcal disease. Microbiology 142:2491-2498.
20. De Moraes, J. C., B. A. Perkins, M. C. C. Camargo, N. T. R. Hidalgo, H. A. Barosa, C. T. Sacchi, I. M. Land Gral, V. L. Gattas, H. D. G. Vasconcelos B. D. Plikaytis, J. D. Wenger, and C. V. Broome. 1992. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340:1074-1078.
21. Finne, J., M. Leinonen, and P. H. Mäkelä. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
22. Frasch, C. E., G. Coetzee, J. M. Zahradnik, H. A. Feldman, and H. J. Koornhof. 1983. Development and evaluation of group B serotype 2 protein vaccines: report of a group B field trial. Med. Trop. (Marseille) 43:177-180.
23. Frasch, C. E., W. D. Zollinger, and J. T. Poolman. 1985. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis. 7:504-510.
24. Fredriksen, J. H., E. Griffiths, E. M. Grotterød, E. A. Høiby, E. Rosenqvist, P. Stevenson, and E. Wedege. 1994. Characterization of high molecular weight components in MenB-vaccine "Folkehelsa," an outer membrane vesicle vaccine against group B meningococcal disease, p. 818-824. In C. J. Conde-Glez, S. Morse, P. Rice, F. Sparling, and E. Calderon (ed.), Pathobiology and immunobiology of Neisseriaceae. Instituto Nacional de Salud Publica, Cuernavaca, Morelos, Mexico.
25. Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Frøholm, A. K. Lindbak, B. Møgster, E. Namork, U. Rye, G. Stabbetorp, R. Winsnes, A. Aase, and O. Closs. 1991. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-80.
26. Frøholm, L. O., D. A. Caugant, E. Holten, E. A. Høiby, E. Rosenqvist, and E. Wedege. 1991. Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis. NIPH Ann. 14:139-146.
27. Garred, P., T. E. Michaelsen, G. Bjune, A. Thiel, and A. Svejgaard. 1993. A low serum concentration of mannan-binding protein is not associated with serogroup B or C meningococcal disease. Scand. J. Immunol. 37:468-470.
28. Griffiss, J. M., B. L. Brandt, D. D. Broud, D. K. Goroff, and C. J. Baker. 1984. Immune responses of infants and children to disseminated infections with Neisseria meningitidis. J. Infect. Dis. 150:71-79.
29. Guttormsen, H.-K., L. M. Wetzler, and A. Næss. 1993. Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease. Infect. Immun. 61:4734-4742.
30. Guttormsen, H.-K., L. M. Wetzler, and C. O. Solberg. 1994. Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease. Infect. Immun. 62:1437-1443.
31. Høgåsen, K., T. Michaelsen, O. J. Mellbye, and G. Bjune. 1993. Low prevalence of complement deficiencies among patients with meningococcal disease in Norway. Scand. J. Immunol. 37:487-489.
32. Høiby E. A., E. Rosenqvist, L. O. Frøholm, G. Bjune, B. Feiring, H. Nøkleby, and E. Rønnild. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 14:147-156.
33. Høiby, E. A., G. Bjune, L. O. Frøholm, J. Eng, A. Halstensen, E. Rosenqvist, E. Rønnild, and E. Wedege. 1991. The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis. NIPH Ann. 14:107-123.
34. Holten, E. 1978. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J. Clin. Microbiol. 9:186-188.
35. Idänpään-Heikkilä, I., E. A. Høiby, P. Chattopadhyay, U. Airaksinen, T. E. Michaelsen, and E. Wedege. 1995. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J. Med. Microbiol. 43:335-343.
36. Jennings, H. J., K. J. Johnson, and L. Kenne. 1983. The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis. Carbohydr. Res. 121:233-241.
37. Jones, D. M., R. Borrow, A. J. Fox, K. A. V. Cartwright, and T. Riordan. 1994. Human antibody response to the meningococcal class 1 protein, p. 848-852. In C. J. Conde-Glez, S. Morse, P. Rice, F. Sparling, and E. Calderon (ed.), Pathobiology and immunology of Neisseriaceae. Instituto Nacional de Salud Publica, Cuernavaca, Morelos, Mexico.
38. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 277:680-685.
39. Mæland, J. A., and E. Wedege. 1989. Serum antibodies to cross-reactive Neisseria outer membrane antigens in healthy persons and patients with meningococcal disease. APMIS 97:774-780.
40. Mandrell, R. E., and W. D. Zollinger. 1989. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect. Immun. 57:1590-1598.
41. Mandrell, R. E., and W. D. Zollinger. 1984. Use of a zwitterionic detergent for the restoration of the antibody-binding capacity of electroblotted meningococcal outer membrane proteins. J. Immunol. Methods 67:1-11.
42. Milagres, L. G., S. R. Ramos, C. T. Sacchi, C. A. E. Melles, V. S. D. Vieira, H. Sato, G. S. Brito, J. C. Moraes, and C. E. Frasch. 1994. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:4419-4424.
43. Moran, E. E., B. L. Brandt, and W. D. Zollinger. 1994. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect. Immun. 62:5290-5295.
44. Orren, A., R. E. Warren, P. C. Potter, A. M. Jones, P. J. Lachmann, and J. T. Poolman. 1992. Antibodies to meningococcal class 1 outer membrane proteins in South African complement-deficient and complement-sufficient subjects. Infect. Immun. 60:4510-4516.
45. Pavliak, V., J. R. Brisson, F. Michon, D. Uhrin, and H. J. Jennings. 1993. Structure of the sialylated L3 lipopolysaccharide of Neisseria meningitidis. J. Biol. Chem. 268:14146-14152.
46. Peeters, C. C. A. M., M. Schuller, J. Westdijk, and J. T. Poolman. 1994. Specificity of bactericidal antibody responses in volunteers immunized with meningococcal B15P1.7,16 outer membrane proteins complexed to polysaccharide C and in patients infected with B15P1.7,16, p. 880-887. In C. J. Conde-Glez, S. Morse, P. Rice, F. Sparling, and E. Calderon (ed.), Pathobiology and immunology of Neisseriaceae. Instituto Nacional de Salud Publica, Cuernavaca, Morelos, Mexico.
47. Peeters, C. C. A. M., H. C. Rümke, L. C. Sunderman, E. M. Rouppe van der Voort, J. Meulenbelt, M. Schuller, A. I. Kuipers, P. van der Ley, and J. T. Poolman. 1996. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14:1009-1015.
48. Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. Høiby, E. Rosenqvist, J. Holst, H. Nøkleby, F. Sotolongo, G. Sierra, C. Huergo, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D. Wenger, and C. V. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:683-691.
49. Poolman, J., C. T. P. Hopman, and H. C. Zanen. 1983. Immunogenicity of meningococcal antigens as detected in patient sera. Infect. Immun. 40:398-406.
50. Rosenqvist, E., S. Hartug, L. O. Frøholm, E. A. Høiby, K. Bøvre, and W. D. Zollinger. 1988. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J. Clin. Microbiol. 26: 1543-1548.
51. Rosenqvist, E., E. A. Høiby, B. Bjune, K. Bryn, D. A. Caugant, O. Closs, J. H. Fredriksen, J. K. Grønnesby, H. Nøkleby, E. Wedege, and L. O. Frøholm. 1992. Meningococcal group B outer membrane vesicle vaccine trial among teen-agers in Norway. Adv. Mod. Biotechnol. La Habana 1:5.2.
52. Rosenqvist, E., E. A. Høiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Rønnild, G. Bjune, and H. Nøkleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
53. Rosenqvist, E., E. A. Høiby, E. Wedege, D. A. Caugant, L. O. Frøholm, B. T. McGuinness, J. Brooks, P. R. Lambden, and J. E. Heckels. 1993. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine. Microb. Pathog. 15:197-205.
54. Rosenqvist, E., E. A. Høiby, E. Wedege, B. Kusceck, and M. Achtman. 1993. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis. 167:1065-1073.
55. Rouppe van der Voort, E. M., B. Kuipers, H. F. Brugghe, L. M. A. van Unen, M. Timmermans, P. Hoogerhout, and J. T. Poolman. 1997. Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines. FEMS Immunol. Med. Microbiol. 17:139-148.
56. Rouppe van der Voort, E. M., P. van der Ley, J. van der Biezen, S. George, O. Tunnela, H. van Dijken, B. Kuipers, and J. Poolman. 1996. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect. Immun. 64: 2745-2751.
57. Sierra, G. V. G., H. C. Campa, N. M. Varacel., I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccines against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-210.
58. Skevakis, L., C. E. Frasch, J. M. Zahradnik, and R. Dolin. 1984. Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis. J. Infect. Dis. 149:387-396.
59. Tomáska, L., and J. Nosek. 1995. Several polymers enhance the sensitivity of the Southwestern assay. Anal. Biochem. 227:387-389.
60. Wedege, E., G. Bjune, L. O. Frøholm, E. A. Høiby, and E. Rosenqvist. 1991. Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial. NIPH Ann. 14:183-186.
61. Wedege, E., K. Bolstad, L. M. Wetzler, and H. K. Guttormsen. 1996. IgG antibody activity against meningococcal class 1 and 3 outer membrane proteins in patient sera: comparison between immunoblot and ELISA analyses, p. 190-191. In W. D. Zollinger, C. E. Frasch, and C. D. Deal (ed.), Abstracts of the 10th International Pathogenic Neisseria Conference. Baltimore, Md.
62. Wedege, E., K. Bryn, and L. O. Frøholm. 1988. Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J. Immunol. Methods 113:51-59.
63. Wedege, E., R. Dalseg, D. A. Caugant, J. T. Poolman, and L. O. Frøholm. 1993. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J. Med. Microbiol. 38:23-28.
64. Wedege, E., and L. O. Frøholm. 1986. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun. 51:571-578.
65. Wedege, E., E. A. Høiby, E. Rosenqvist, and L. O. Frøholm. 1990. Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J. Med. Microbiol. 31:195-201.
66. Wedege, E., J. Kolberg, A. Delvig, E. A. Høiby, E. Holten, E. Rosenqvist, and D. A. Caugant. 1995. Emergence of a virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway. Clin. Diagn. Lab. Immunol. 2:314-321.
67. Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunological response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514-522.
68. Zollinger, W. D., J. W. Boslego, E. E. Moran, B. L. Brandt, C. Cruz, M. Martinez, and J. Garcia. 1994. Effect of vaccination with meningococcal outer membrane protein vaccine on subsequent antibody reponses to carriage and natural infections, p. 954-960. In C. J. Conde-Glez, S. Morse, P. Rice, F. Sparling, and E. Calderon (ed.), Pathobiology and immunobiology of Neisseriaceae. Instituto Nacional de Salud Publica, Cuernavaca, Morelos, Mexico.
69. Zollinger, W. D., and E. Moran. 1991. Meningococcal vaccines - present and future. Trans. R. Soc. Trop. Med. Hyg. 85(Suppl. 1):37-43.